paliperidone palmitate - Profile

What are the generic drug sources for paliperidone palmitate and what is the scope of patent protection?

Paliperidone palmitate is the generic ingredient in four branded drugs marketed by Luye Innomind Pharma and Janssen Pharms, and is included in three NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Paliperidone palmitate has one hundred and eighty-nine patent family members in thirty-six countries.

There are five tentative approvals for this compound.

Summary for paliperidone palmitate

International Patents:	189
US Patents:	8
Tradenames:	4
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for paliperidone palmitate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for paliperidone palmitate

Constraining patent/regulatory exclusivity:

11,666,573

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

10,143,693

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

5,254,556

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for PALIPERIDONE PALMITATE

Applicant	Application No.	Strength	Dosage Form
			SUSPENSION;EXTENDED RELEASE
		234MG/1.5ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
		156MG/ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for PALIPERIDONE PALMITATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24
INVEGA SUSTENNA	Extended-release Injectable Suspension	paliperidone palmitate	39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	022264	1	2017-11-21

US Patents and Regulatory Information for paliperidone palmitate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-001	Jul 26, 2024		RX	Yes	Yes	11,666,573
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-001	Jul 26, 2024		RX	Yes	Yes	12,128,049
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-002	Jul 26, 2024		RX	Yes	Yes	11,666,573
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-002	Jul 26, 2024		RX	Yes	Yes	12,128,049
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-003	Jul 26, 2024		RX	Yes	Yes	11,666,573
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-003	Jul 26, 2024		RX	Yes	Yes	12,128,049

International Patents for paliperidone palmitate

Country	Patent Number	Title	Estimated Expiration
Australia	2016244801
Australia	2020239611
Australia	2022221405
Australia	2024227790
Brazil	112017021383
Canada	2925908

Supplementary Protection Certificates for paliperidone palmitate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0904081	11C0035	France		PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	2011/021	Ireland		PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
0904081	SPC/GB11/044	United Kingdom		PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625

Investment Scenario, Market Dynamics, and Financial Trajectory of Paliperidone Palmitate

Last updated: February 3, 2026

Summary

Paliperidone palmitate, marketed as Invega Sustenna and Invega Trinza, is a long-acting injectable antipsychotic used primarily in schizophrenia management. Its market outlook depends on rising global mental health awareness, expanding indications, competitive landscape, regulatory developments, and manufacturing innovations. This report evaluates current market size, growth drivers, key competitors, financial projections, and strategic considerations relevant to investors in this pharmaceutical segment.

---

Introduction to Paliperidone Palmitate

Parameter	Details
Generic Name	Paliperidone Palmitate
Brand Names	Invega Sustenna, Invega Trinza
Therapeutic Class	Long-acting antipsychotic
Indications	Schizophrenia, schizoaffective disorder (approved in multiple countries; off-label uses increasing)
Administration	Monthly (Sustenna), quarterly (Trinza)

---

Market Size and Growth Drivers

Global Market Overview (2023)

Region	Market Size (USD Billion)	CAGR (2023–2028)	Notes
North America	2.2	4.5%	Dominant due to high schizophrenia prevalence and reimbursement coverage
Europe	1.1	4.2%	Growing awareness, expanding treatment guidelines
Asia-Pacific	0.9	9.8%	Rapid market growth, increased healthcare access
Rest of World	0.4	6.0%	Improving healthcare infrastructure

Total Market (2023): Approximately USD 4.6 billion, projected to reach USD 6.1 billion by 2028.

Key Growth Drivers

• Prevalence of Schizophrenia: Estimated at 20 million globally, with increasing diagnosis rates.
• Preference for Long-acting Injectables (LAIs): Reduces adherence issues, increases compliance.
• Off-label and Expanded Indications: Ongoing studies for bipolar disorder, irritability associated with autism, and other psychiatric conditions.
• Healthcare Policy and Reimbursement: Favorable policies in developed countries bolster adoption rates.
• Innovation in Formulation and Delivery: Newer formulations with improved efficacy and fewer side effects.

---

Market Dynamics and Competitive Landscape

Major Competitors

Company	Product(s)	Market Share (%)	Competitive Advantages
Johnson & Johnson	Invega Sustenna, Invega Trinza	55	Extensive clinical data, brand recognition
Alvotech	AVT02	Niche	Biosimilar, lower-cost alternative (pending approval)
Otsuka	Abilify Maintena (oral), Vanquish (injectable)	20	Strong pipeline, combination approaches
Others	Risperdal Consta, Aristada	5	Differentiated mechanisms, dose flexibility

Regulatory and Patent Landscape

• Patent Expirations: Patents for Invega Sustenna expiring between 2025–2028, opening opportunities for biosimilars or generics.
• Regulatory Approvals: Broad approvals in North America, Europe, Asia; ongoing submissions in emerging markets.
• Reimbursement Policies: Coverage varies; in the U.S., Medicaid and private insurers cover LAIs predominantly.

---

Financial Trajectory and Investment Analysis

Historical Revenue Performance (2020–2022)

Year	Revenue (USD Billion)	Growth Rate (%)	Notes
2020	1.55	-	Pandemic effects, delayed initiatives
2021	1.68	8.4	Resumption of prescribing patterns
2022	1.76	4.8	Gradual recovery, pipeline expansion

Forecasted Revenue (2023–2028)

Year	Projected Revenue (USD Billion)	Compound Annual Growth Rate (CAGR)	Key Assumptions
2023	1.85	5.1%	Higher adoption rates, pipeline contribution
2024	1.94	4.9%	Expanded indications, emerging biosimilar competition
2025	2.07	6.1%	Patent expiries, biosimilar market entry
2026	2.25	8.2%	Market penetration, off-label uses
2027	2.44	8.2%	New formulations, evolving reimbursement policies
2028	2.61	6.9%	Market saturation starts, price adjustments

Profitability and Investment Considerations

Parameter	Figures/Comments
Gross Margin	~70% consistent with branded biologics
Operating Margin	25–30%, impacted by R&D and marketing spend
Market Penetration Opportunities	Expanding into emerging markets, biosimilar launches post-patent expiry
Risks	Regulatory delays, biosimilar competition, reimbursement shifts

---

Strategic Opportunities and Challenges

Opportunities	Challenges
Licensing and partnership deals in Asia and Africa	Patent cliffs potentially leading to price erosion
Development of biosimilars	Off-label use risks and regulatory scrutiny
Formulation innovations (e.g., auto-injectors)	Pricing pressures from healthcare systems
Expansion into other psychiatric indications	Societal stigma impacting diagnosis rates

---

Comparison with Similar Drugs

Drug	Active Ingredient	Administration Frequency	Market Size (2023)	Key Competitors
Risperdal Consta	Risperidone	Biweekly/monthly	USD 0.4 B	Otsuka, Janssen
Abilify Maintena	Aripiprazole	Monthly	USD 0.6 B	Otsuka, Johnson & Johnson
Lacrisert	Carbomer eye insert	Weekly	USD 0.2 B	Novartis

Paliperidone palmitate's advantage lies in its dosing flexibility and proven efficacy profiles, enabling sustained growth amid a crowded field.

---

Regulatory and Policy Landscape

Region	Regulatory Status	Reimbursement Policies	Implications
North America	Approved (FDA, Health Canada)	Favorable	High adoption; favorable reimbursement
Europe	EMA approvals	Widely reimbursed	Stable growth potential
Asia-Pacific	Varying approvals; some pending	Growing coverage	Significant growth prospects

---

FAQs

1. What factors most influence investor confidence in paliperidone palmitate?
Market growth driven by increased prevalence, reimbursement policies, and formulation innovations; patent expirations and biosimilar competition pose risks.

2. How does patent expiry affect the financial forecast?
Expected patent cliffs by 2025–2028 can lead to biosimilar entry, reducing brand pricing power and margins, but also presenting opportunities for lower-cost alternatives.

3. What are the main competitive advantages of paliperidone palmitate?
Efficacy in reducing relapse, extended dosing intervals (monthly and quarterly), favorable safety profile, and established patient adherence.

4. Which emerging markets offer the greatest growth potential?
Asia-Pacific and Latin America, due to rising mental health awareness, expanding healthcare infrastructure, and increasing diagnosis rates.

5. How might regulatory developments impact clinical deployment?
Stringent approval pathways, off-label use restrictions, and biosimilar regulations will influence market penetration and financial outcomes.

---

Key Takeaways

• Market Position: Paliperidone palmitate remains a dominant long-acting injectable for schizophrenia, with a 2023 global market size of approximately USD 4.6 billion and projected CAGR over 5%.
• Growth Catalysts: Increasing prevalence, preference for LAIs, and expanding indications fuel demand. Regulatory approvals in emerging markets further expand opportunities.
• Challenges: Patent expiries, biosimilar threats, and reimbursement variability necessitate strategic innovation and partnership.
• Financial Outlook: Revenue growth expected at ~5-6% annually through 2028, with profitability supported by high gross margins and expanding markets.
• Strategic Considerations: Opportunities in biosimilar development, formulation innovations, and entry into high-growth regions can enhance investor returns.

---

References

1. MarketsandMarkets, "Schizophrenia Treatment Market," 2023.
2. Johnson & Johnson Annual Reports, 2020–2022.
3. GlobalData, "Pharmaceutical Industry Insights," 2023.
4. FDA and EMA approval documents, 2023.
5. WHO Mental Health Data, 2022.